Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2022-04-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 2021年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company 百奥泰生物制药股份有限公司 in 2021. It includes specifics on the amount raised, usage of funds, storage, investment projects, changes in project funding, and compliance with regulatory requirements. It references regulatory guidelines related to the management and use of raised funds and includes verification opinions from an accounting firm and the sponsor institution. The document is not a general annual report or earnings release but a specialized report focused on the use of capital raised through a public offering. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (8855 characters) and content indicate it is the report itself, not merely an announcement of a report publication. Therefore, the appropriate classification is CAP.
2022-04-28 Chinese
百奥泰 关于公司2022年度董事、监事和高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2022 annual remuneration scheme for the company's directors, supervisors, and senior management. It details the salary arrangements and independent directors' opinions on the remuneration plan. It references compliance with company law and governance rules but does not contain financial statements or performance data. The document is a disclosure of remuneration information rather than a full compensation report or proxy statement. Therefore, it fits best under the Remuneration Information category (DEF 14A). The document length and content confirm it is not a brief announcement or a full annual report but a detailed remuneration disclosure.
2022-04-28 Chinese
百奥泰2021年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by Ernst & Young Hua Ming LLP for 百奥泰生物制药股份有限公司 regarding the 2021年度非经营性资金占用及其他关联资金往来情况 (non-operating fund occupation and other related party fund transactions). It includes detailed tables and explanations about these specific financial matters and references the audit procedures performed. The document is not a full annual report but a standalone audit-related report focusing on a specific regulatory requirement under the "上市公司监管指引第 8 号". It is issued by a certified accounting firm and contains substantive financial data and audit findings related to the company's 2021 fiscal year. This fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification letter.
2022-04-28 Chinese
百奥泰2021年度审计报告
Audit Report / Information Classification · 100% confidence The document is an audit report for 百奥泰生物制药股份有限公司 (Bio-Thera Solutions Ltd.) for the fiscal year 2021. It includes detailed auditor opinions, key audit matters, audit procedures, and the audited financial statements such as consolidated balance sheets, income statements, cash flow statements, and notes to the financial statements. The report is issued by Ernst & Young Hua Ming LLP, a registered accounting firm, and contains the auditor's signature and report date. The content is comprehensive and contains actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories.
2022-04-28 Chinese
百奥泰 独立董事关于公司对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 90% confidence The document is a special statement and independent opinion by the independent directors regarding the company's external guarantees for the fiscal year 2021. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The content is a specific assurance about the absence of external guarantees during the reporting period, without detailed financial data or comprehensive report content. The document length is very short (319 characters), and it serves as a regulatory compliance statement rather than a full audit or annual report. Therefore, it fits best under Audit Report / Information (AR) as it relates to a specific audit-related disclosure about external guarantees, not a full annual report or other category.
2022-04-28 Chinese
百奥泰2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The presence of an audit report with an unqualified opinion from Ernst & Young Hua Ming LLP is mentioned, and the document includes comprehensive financial metrics, quarterly data, and extensive narrative on business operations and strategy. The length of the document (15,000 characters) and the detailed content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2022-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.